Hydroxychloroquine Efficacy on Behcet's Disease Thrombosis
Status:
Unknown status
Trial end date:
2019-10-01
Target enrollment:
Participant gender:
Summary
Patients diagnosed with Behcet's disease will be randomized to administeration of
hydroxychloroquine. Assessment will be done for the patients at baseline and every one month
in the first three months and then quarterly for one year.